Ironwood reiterates FY2025 LINZESS guidance, raises EBITDA to >$105M; Q1 net sales down 46%

IRONWOOD PHARMACEUTICALS INC

2025-Q1 EPS reported -$0.23 revenue$41,143,000

Reiterates FY2025 LINZESS U.S. net sales guidance of $800-$850M and total revenue of $260-$290M.
Raises FY2025 adjusted EBITDA guidance to >$105M (from >$85M).
Q1 2025 LINZESS U.S. net sales were $138.5M, a 46% decrease YoY due to change in AbbVie's gross-to-net rebate estimate.
Q1 2025 LINZESS prescription demand grew 8% YoY to 53M capsules, per IQVIA.
Shifts apraglutide focus to confirmatory Phase 3 trial after FDA feedback; no longer plans certain commercial launch investments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.